Read by QxMD icon Read

Breast cancer her2+ recurrence

Mai Temukai, Hajime Hikino, Yoshinari Makino, Yoko Murata
Liver metastasis from breast cancer usually results in the development of systemic metastasis. We report a breast cancer patient with an early isolated liver recurrence who survived more than 7 years with no recurrence. She was treated with aggressive HER2-directed chemotherapy and hepatic metastasectomy. Local hepatectomy with effective medical oncological therapy with curative intent is worth trying in patients with breast cancer liver metastasis.
December 2017: Surgical Case Reports
F Qian, Y Qingping, W Linquan, H Xiaojin, W Rongshou, R Shanshan, L Wenjun, H Yong, L Enliang
AIMS: Tumor-infiltrating FoxP3(+) T cells and FoxP3(+) tumor cells have been reported in breast cancer (BC), which impaired immunity and promoted tumors progression. However, their prognostic value for survival in patients with breast BC remains controversial. METHODS: A meta-analysis was performed. Original data included the hazard ratios (HR) of overall survival (OS), relapse-free survival and odds ratio (OR) in BC patients. We pooled HR/OR with 95% confidence intervals (CI) to estimate the hazard...
January 30, 2017: European Journal of Surgical Oncology
Carlos H Barcenas, Akshara Raghavendra, Arup K Sinha, Masood Pasha Syed, Limin Hsu, Modesto G Patangan, Mariana Chavez-MacGregor, Yu Shen, Gabriel H Hortobagyi, Vicente Valero, Sharon H Giordano, Naoto T Ueno, Debu Tripathy
BACKGROUND: Invasive disease-free survival (IDFS) rates are excellent in patients with breast cancer (BC) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), axillary lymph node-negative (LN-) tumors with a 21-gene expression assay recurrence score (RS) of 0 to 10. However, to the authors' knowledge, the outcomes among patients with an RS of 11 to 25 who are treated with endocrine therapy alone are unknown. METHODS: In this retrospective single-institution study, the authors described the characteristics of patients with HR+, HER2-, LN- BC who underwent a 21-gene expression assay...
February 15, 2017: Cancer
Mayada Saad Farrag, Amro Awad El-Karef, Maha Mohammed Amin, Nagwa Mokhtar Helal, Omar Farouk Ali, Nesrine Saad Farrag
BACKGROUND: Calretinin (CR), a known mesothelial marker, is expressed in both epithelial and mesenchymal malignancies including breast cancer. AIMS: We aimed to measure the frequency of CR expression in correlation with other clinicopathological parameters of different molecular subtypes of invasive breast carcinoma and to study its prognostic implications in this common cancer. STUDY DESIGN: Tissue microarrays were constructed from 225 tissue samples of breast carcinoma cases...
January 2017: Indian Journal of Pathology & Microbiology
Mengjiao Li, Haoran Li, Fei Liu, Rui Bi, Xiaoyu Tu, Lihua Chen, Shuang Ye, Xi Cheng
BACKGROUND: It has long been appreciated that different subtypes (serous, clear cell, endometrioid and mucinous) of epithelial ovarian carcinoma (EOC) have distinct pathogenetic pathways. However, clinical management, especially chemotherapeutic regimens, for EOC patients is not subtype specific. Ovarian clear cell carcinoma (CCC) is a rare histological subtype of EOC, which exhibits high rates of recurrence and low chemosensitivity. We assessed potential therapeutic targets for ovarian CCC patients through analyzing the variation of drug-based molecular biomarkers expression between ovarian CCC and high-grade serous carcinoma (HGSC)...
February 10, 2017: Journal of Ovarian Research
Min Hye Jang, Hyun Jung Kim, Yul Ri Chung, Yangkyu Lee, So Yeon Park
In spite of the usefulness of the Ki-67 labeling index (LI) as a prognostic and predictive marker in breast cancer, its clinical application remains limited due to variability in its measurement and the absence of a standard method of interpretation. This study was designed to compare the two methods of assessing Ki-67 LI: the average method vs. the hot spot method and thus to determine which method is more appropriate in predicting prognosis of luminal/HER2-negative breast cancers. Ki-67 LIs were calculated by direct counting of three representative areas of 493 luminal/HER2-negative breast cancers using the two methods...
2017: PloS One
Roberta Maltoni, Valentina Casadio, Sara Ravaioli, Flavia Foca, Maria Maddalena Tumedei, Samanta Salvi, Filippo Martignano, Daniele Calistri, Andrea Rocca, Alessio Schirone, Dino Amadori, Sara Bravaccini
As conventional biomarkers for defining breast cancer (BC) subtypes are not always capable of predicting prognosis, search for new biomarkers which can be easily detected by liquid biopsy is ongoing. It has long been known that cell-free DNA (CF-DNA) could be a promising diagnostic and prognostic marker in different tumor types, although its prognostic value in BC is yet to be confirmed. This retrospective study evaluated the prognostic role of CF-DNA quantity and integrity of HER2, MYC, BCAS1 and PI3KCA, which are frequently altered in BC...
February 6, 2017: Oncotarget
Lauren Nye, Alfred Rademaker, William J Gradishar
BACKGROUND: Counseling patients regarding the risk of future pregnancy on hormone receptor-positive breast cancer outcomes is difficult because of the minimal data and understanding of pregnancy on the breast environment. PATIENTS AND METHODS: The present retrospective analysis included 32 premenopausal women with a diagnosis of estrogen receptor-positive breast cancer from 2000 to 2010 and subsequent pregnancy within 5 years. The control cohort included 29 women matched for age and stage of breast cancer who had not become pregnant...
January 9, 2017: Clinical Breast Cancer
Sebastiano Bordonaro, Massimiliano Berretta, Antonino Carmelo Tralongo, Silvia Clementi, Brigida Stanzione, Paolo Tralongo
Over the last 15 years, we have seen a huge expansion of the development of drugs directed against biomolecular targets within breast cancer cells. The over-expression of certain receptors (ER, PgR, HER-2, VEGF-R), as well as alteration of several intracellular signal transduction pathways (the PI3K-AKT-mTOR pathway, MEK-MAPK pathway, loss of PTEN, etc ...) have a great impact on the likelihood of recurrence and progression of the disease, influencing the natural history of breast cancer. The recent biomolecular classification of breast cancer (Luminal A / B, HER2-driven, Basal Like) allowed finally to identify specific treatments against molecular target to associate or not to traditional chemotherapy, and to use in relation to the prognosis of the disease...
February 8, 2017: Current Cancer Drug Targets
Jun-Long Song, Chuang Chen, Jing-Ping Yuan, Juan-Juan Li, Sheng-Rong Sun
OBJECTIVE: Whether a first-degree family history of others cancers (FHOC) than breast or ovarian cancer (BOC) is associated with breast cancer prognosis remains unknown. Thus, the aim of the present study was to clarify this issue. METHODS: Women who were diagnosed with invasive breast cancer at the Renmin Hospital of Wuhan University from 2010 to 2013 were included in the study. The demographic and clinicopathological characteristics of these patients were extracted...
February 5, 2017: Breast: Official Journal of the European Society of Mastology
Matthew G Hanna, Ira J Bleiweiss, Anupma Nayak, Shabnam Jaffer
Oncotype Dx is used to determine the recurrence risk (RR) in patients with estrogen receptor positive (ER+) and lymph node negative (LN-) breast cancer. The RR is divided into low (0-17), intermediate (18-30), and high (31) to predict chemotherapy benefit. Our goal was to determine the association between histomorphology, immunohistochemistry, and RR. We retrospectively identified 536 patients with ER+ and LN- breast cancers that underwent Oncotype testing from 2006 to 2013. Tumor size ranged from 0.2 cm to 6...
2017: International Journal of Breast Cancer
Huafeng Yang, Liang Chen, Linfu Zhou, Chun Liu, Lubing Tang, Jing Zhang, Fengfeng Fan, Zhenhua Zhong, Guojun Shi, Zhanwen Li
BACKGROUND: The aim of this study was to evaluate the predictive value of serum human epidermal growth factor 2 (HER2) for recurrence and metastasis in triple negative breast cancer (TNBC). METHODS: A total of 200 patients with benign breast tumors and 300 patients with breast cancer treated in the Department of Breast Surgery, Women and Children's Hospital of Ningbo City (China) between December 2006 and December 2013 were enrolled. Another 500 age- and gender-matched healthy individuals served as controls...
January 1, 2017: Clinical Laboratory
Tonghui Wang, Ye Xu, Shuyan Sheng, Hua Yuan, Tao Ouyang, Jinfeng Li, Tianfeng Wang, Zhaoqing Fan, Tie Fan, Benyao Lin, Yuntao Xie
It is well documented that HER2 overexpression/amplification is associated with the poor survival in breast cancer patients. However, it is largely unknown whether HER2 somatic mutations are associated with the survival in HER2-negative breast cancer patients. Here, we identified HER2 somatic mutations in tumors from 1,348 unselected breast cancer patients by sequencing the entire HER2 coding region. All these mutations were tested for in corresponding blood samples to determine whether they were somatic or germline mutations...
February 6, 2017: Cancer Science
Alexandre de Nonneville, Anthony Gonçalves, Christophe Zemmour, Jean M Classe, Monique Cohen, Eric Lambaudie, Fabien Reyal, Christophe Scherer, Xavier Muracciole, Pierre E Colombo, Sylvia Giard, Roman Rouzier, Richard Villet, Nicolas Chopin, Emile Darai, Jean R Garbay, Pierre Gimbergues, Laura Sabiani, Charles Coutant, Renaud Sabatier, François Bertucci, Jean M Boher, Gilles Houvenaeghel
PURPOSE: Benefit of adjuvant trastuzumab-based chemotherapy for node-positive and/or >1 cm human epidermal growth factor receptor 2-positive (HER2+) breast carcinomas has been clearly demonstrated in randomized clinical trials. Yet, evidence that adjuvant chemotherapy with or without trastuzumab is effective in pT1abN0 HER2+ tumors is still limited. The primary objective of this study was to investigate the impact of adjuvant chemotherapy ± trastuzumab on outcome in this subpopulation...
February 2, 2017: Breast Cancer Research and Treatment
Nahed A Soliman, Shaimaa M Yussif
OBJECTIVE: Ki-67 plays an important function in cell division, but its exact role is still unknown. Moreover, few works regarding its overall function were published. The present study evaluated the clinical significance of Ki-67 index as a prognostic marker and predictor of recurrence in different molecular subtypes of breast cancer. The relationship of Ki-67 index with different clinicopathological factors was also analyzed. METHODS: Ki-67 index was measured in 107 cases of primary breast cancer from 2010-2012...
December 2016: Cancer Biology & Medicine
Valentina Petkov, Dave P Miller, Nadia Howlader, Nathan Gliner, Will Howe, Nicola C Schussler, Kathleen Cronin, Frederick L Baehner, Lynne Penberthy
: 176 Background: NCI's SEER Program provides cancer incidence and survival statistics for ~28% of the US. New research models are needed to characterize the use and impact of genomic tests on patient outcomes. Genomic Health and SEER collaborated to electronically supplement SEER registries with Recurrence Score (RS) results, and have evaluated breast cancer specific mortality (BCSM) in early stage hormone receptor (HR)+ HER2- invasive breast cancer. METHODS: Pts were eligible for pre-specified node negative (N-) disease analysis if HR+, HER2- (by RT-PCR), no prior malignancy, 40-85 years of age, and diagnosed between Jan 2004 (Oncotype DX available Jan 2004) and Dec 2011 (SEER survival analysis complete through 2012)...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Nancy K Janz, Reshma Jagsi, Kent A Griffith, Christopher Ryan Friese, Allison W Kurian, Monica Morrow, Lauren P Wallner, Steven J Katz
: 175 Background: Many breast cancer patients overestimate their risk of distant recurrence after treatment. We explored risk perception in a large, diverse population of breast cancer patients with favorable prognosis and assessed associations between overestimation and quality of life (QoL). METHODS: As part of the iCanCare Study, we surveyed a weighted random sample of newly diagnosed patients with early-stage breast cancer treated in 2013-14, identified through the population-based SEER registries of Los Angeles & Georgia about 3 months after surgical treatment (N = 2632, RR = 70%)...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
I P C Buzatto, A Ribeiro-Silva, J M Andrade, H H A Carrara, W A Silveira, D G Tiezzi
The purpose of this study was to retrospectively review the pathologic complete response (pCR) rate from patients (n=86) with stage II and III HER2-positive breast cancer treated with neoadjuvant chemotherapy at our institution from 2008 to 2013 and to determine possible predictive and prognostic factors. Immunohistochemistry for hormone receptors and Ki-67 was carried out. Clinical and pathological features were analyzed as predictive factors of response to therapy. For survival analysis, we used Kaplan-Meier curves to estimate 5-year survival rates and the log-rank test to compare the curves...
January 26, 2017: Brazilian Journal of Medical and Biological Research, Revista Brasileira de Pesquisas Médicas e Biológicas
Stephen A Mihalcik, Bhupendra Rawal, Lior Z Braunstein, Alex Capuco, Julia S Wong, Rinaa S Punglia, Jennifer R Bellon, Jay R Harris
PURPOSE: Risk factors for local recurrence (LR) following breast-conserving therapy (BCT) inform the need for local therapy. A Danish population-based cohort study identified residual disease on reexcision as an independent risk factor for LR but was limited by incomplete data on biologic subtype (Bodilsen et al. 2015 in Ann Surg Oncol 22: S476-S485). We sought to elaborate this risk in an independent cohort with clearly defined biologic subtypes. METHODS: The study population included patients with localized invasive breast cancer with complete biologic subtype data treated with BCT with one or zero reexcisions at one institution from 1998 to 2008...
January 30, 2017: Annals of Surgical Oncology
Yasumoto Yamasaki, Yasuhiro Yamasaki, Jun Tsuboi
The patient, a 57-year-old man, observed an elastic hard tumor under his left areola. Ultrasonography showed a circular hypoechoic mass that was 1.5 cm in diameter with a moderately indistinct border. Using fine needle aspiration cytology, the tumor was diagnosed as a ductal carcinoma(T1N0M0, stage I ). The patient underwent a mastectomy and a sentinel lymph node biopsy. We omitted radical axillary lymph node dissection because there were no metastases in the sentinel lymph node according to intraoperative frozen section diagnosis...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"